Drug Channels

MARCH 4, 2025

Emerging controversies, challenges, and threats to watch in the industry And much more!

Specialty Pharmacies 94

Specialty Pharmacies Drug Pricing Labelling 94

Proxsys Rx

DECEMBER 11, 2023

At the same time, it’s no secret that, since the advent of 340B ESP in 2020, the drug manufacturers have imposed a raft of restrictions on 340B program savings that exist far outside the letter of the law as written by Congress in 1992. Every specialty pharmacy patient you serve should be monitored by a clinic pharmacist.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Labelling 52

Proxsys Rx

MARCH 1, 2024

At the same time, it’s no secret that, since the advent of 340B ESP in 2020, the drug manufacturers have imposed a raft of restrictions on 340B program savings that exist far outside the letter of the law as written by Congress in 1992. Every specialty pharmacy patient you serve should be monitored by a clinic pharmacist.

Specialty Pharmacies 40

Specialty Pharmacies Hospitals Drug Pricing Labelling 40

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). It is crucial to consider how off-label uses will be evaluated and incorporated into the negotiation process.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Putting Patients First Blog

JANUARY 27, 2025

3 ,4, 5 As such, the NHC supports CMS proposal to ensure that Part D sponsors cover AOMs for obesity with clinical criteria that is not more restrictive than the FDA labeling for each AOM. Issue Brief: Improving Prescription Drug Price and Cost Transparency. 14 National Health Council. 2024.30.2.206. Accessed January 2, 2025.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40